Melanotan I is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data. Melanotan I is fda-approved as scenesse for epp only (prescription). not approved for cosmetic tanning.
What Does the Research Say About Melanotan I?
Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Research interest has focused on its potential effects on skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
What Is the Evidence for Melanotan I's Mechanism?
Selectively binds MC1R on melanocytes, triggering the cAMP-dependent signaling cascade that increases MITF transcription factor activity. This upregulates tyrosinase enzyme expression and melanin synthesis, producing skin darkening without requiring UV exposure.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for Melanotan I?
Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, Melanotan I has shown encouraging results.
What Does the Safety Research Show?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
Melanotan I is fda-approved as scenesse for epp only (prescription). not approved for cosmetic tanning.
What Makes Melanotan I Unique in Research?
The only Melanotan analog with FDA approval and extensive Phase III clinical trial data — far better characterized for safety than the more popular (but more dangerous) Melanotan II.
This differentiator is important because it means Melanotan I fills a role that other compounds in its class may not fully replicate.
Bottom Line on Melanotan I Research
The evidence base for Melanotan I is growing. Key research areas include skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
Stay current with PubMed searches for Melanotan I for the latest publications.
Complete Guide
Melanotan I : Benefits, Dosage, Side Effects & Research
Related Reading
- Melanotan I Dosage Guide
- Melanotan I Benefits
- Melanotan I Side Effects
- Melanotan I Stacking Guide
- Melanotan I Cycle Guide
- ARA-290 Complete Guide
Calculate Your Melanotan I Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Melanotan I.
Open Calculator →Research-Grade Sourcing
If you're going to research Melanotan I, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Melanotan I?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation. It is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
What is the recommended Melanotan I dosage?
Common dosages: 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) via subcutaneous implant (approved) or subcutaneous injection. Cycle length: 60-day implant cycles; 4-8 weeks injection cycles. Half-life: ~2 hours circulating; implant provides 2-month depot release. Use our peptide calculator for exact reconstitution math.
What are the side effects of Melanotan I?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
Is Melanotan I safe?
Melanotan I has shown a preliminary safety profile in research. FDA-approved as Scenesse for EPP only (prescription). Not approved for cosmetic tanning. All research should follow appropriate safety protocols.